Please assess the completion status of the following clinical trial:

Trial Title: Remifentanil Minimum Effective Dose for Children Intubation Without Neuromuscular Blockade

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I or II~* Scheduled for surgery under general anesthesia.~Exclusion Criteria:~* Predicted difficult airway~* Severe neurologic or cardiologic conditions~* Recent upper airway infectious diseases

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 9 Years
- Healthy Volunteers: t

Study Arms:
- Study arm (Type: EXPERIMENTAL): There is a single study arm. Remifentanil will be infused before intubation. The first patient will receive remifentanil 2mg/kg. If a success occurs the next patient's dose will be decreased by 0.25mg/kg and else it will be increased by 0.25mg/kg. This rule will apply recursively as Dixon's Up-And-Down Method.

Based on this trial design, predict the completion outcome and termination type (if applicable).